These Biotech Stocks Are Pricey, but Investors Can Still Buy Them

These Biotech Stocks Are Pricey, but Investors Can Still Buy Them

Sarepta Therapeutics (NASDAQ: SRPT) and Amicus Therapeutics (NASDAQ: FOLD) are two fast-growing biotech stocks that are trading at price-to-sales multiples north of 50, yet biotech investors may still want to add them to their portfolios despite their sky-high valuations. Both companies already market fast-growing, FDA-approved drugs and each is developing new drugs for rare diseases that could significantly expand their peak sales opportunity. 

Sarepta Therapeutics markets Exondys 51, an exon-skipping drug that helps restore dystrophin production in about 13% of Duchenne's muscular dystrophy (DMD) patients. 

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source: Fool.com